3.6. Gastrointestinal (GI) Tolerance and Safety
cancer
ADVERSE EVENTS, CANCER
Subjects in the IG reported more adverse events (AEs) compared to the CG 66.7% vs. 28.6%, respectively, and the difference was statistically significant (The medical history and concomitant medications of the participating subjects were representative of the cancer population. None of the subjects presented with any of the prohibited ailments at the inclusion in the study. Based on the available data, no major health concerns were observed in this study.